Premium
Response assessment in W aldenström macroglobulinaemia: update from the VI th I nternational W orkshop
Author(s) -
Owen Roger G.,
Kyle Robert A.,
Stone Marvin J.,
Rawstron Andy C.,
Leblond Veronique,
Merlini Giampaolo,
GarciaSanz Ramon,
Ocio Enrique M.,
Morra Enrica,
Morel Pierre,
Anderson Kenneth C.,
Patterson Christopher J.,
Munshi Nikhil C.,
Tedeschi Alessandra,
Joshua Douglas E.,
Kastritis Efstathios,
Terpos Evangelos,
Ghobrial Irene M.,
Leleu Xavier,
Gertz Morie A.,
Ansell Stephen M.,
Morice William G.,
Kimby Eva,
Treon Steven P.
Publication year - 2013
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12102
Subject(s) - medicine , waldenstrom macroglobulinemia , clinical trial , bone marrow , intensive care medicine , oncology , immunology , lymphoma
Summary This report represents a further update of the consensus panel criteria for the assessment of clinical response in patients with W aldenström macroglobulinaemia ( WM ). These criteria have been updated in light of further data demonstrating an improvement in categorical responses with new drug regimens as well as acknowledgement of the fact that such responses are predictive of overall outcome. A number of key changes are proposed but challenges do however remain and these include the variability in kinetics of immunoglobulin M ( IgM ) reduction with different treatment modalities and the apparent discrepancy between IgM and bone marrow/tissue response noted with some regimens. Planned sequential bone marrow assessments are encouraged in clinical trials.